Clinical Trials Directory

Trials / Unknown

UnknownNCT03749525

Shenfu Injection Improves Arterial Vascular Reactivity

Effect of Shenfu Injection on Arterial Vascular Reactivity in Patients With Septic Shock

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
26 (estimated)
Sponsor
Jianfeng Xie · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Septic shock is a common and critical illness in ICU.The vascular dysfunction of septic shock is manifested by vasospasm and decreased arterial vascular reactivity . Current studies have shown that the main mechanisms of vasospasm and decreased arterial vascular reactivity include increased vasospasm and down-regulation of receptor sensitivity , and eventually cause a decrease in vascular smooth muscle contractility.A large number of vasodilators are released during septic shock, in which inducible nitric oxide synthase (iNOS) and prostacyclin (PGI2) are important vasodilators leading to septic shock vasospasm.At present, vasoactive drugs are widely used in clinically to improve vascular tone and are important means of circulation support. However, when the infection is heavier, the reactivity of the blood vessels to the vasoactive drugs is lowered, and it is difficult for the large doses of the vasoactive drugs to maintain the circulation stability. At this time, the use of vasoactive drugs alone does not benefit patients with septic shock and may require the combination of other drugs.From the perspective of Chinese medicine, shock is a disease of yang. Shenfu injection has the effect of rejuvenating the yang and replenishing the qi. This trial was designed to give patients with septic shock the use of Shenfu injection to determine the specific effects of Shenfu injection on vascular reactivity in patients with septic shock.

Conditions

Interventions

TypeNameDescription
DRUGshenfu injectionwe hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock

Timeline

Start date
2018-12-01
Primary completion
2019-08-01
Completion
2019-09-01
First posted
2018-11-21
Last updated
2018-11-21

Source: ClinicalTrials.gov record NCT03749525. Inclusion in this directory is not an endorsement.